Tools chosen: kalshi_direct kalshi_related claude_news gdelt_news code_execution wikipedia polymarket_related

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market on a 4-year cumulative-average threshold: averaging ≥5,000 US measles cases/year over 2025-2028 requires ~20,000 total cases, versus ~1,300 in 2025's record year (worst since 1992) — so the key empirical inputs are the actual 2025 CDC count, the 2026 running count, vaccination-rate/elimination-status trends, and whether resolution uses CDC US case counts. The market price is the primary anchor, and simple arithmetic on required future-year counts sharply constrains the probability.

# Event Kalshi market asking whether the average annual US measles case count over 2025–2028 (Trump Administration) will be at least 5,000. # Outcomes to forecast - Yes (4-yr average ≥ 5,000/year) - No (4-yr average < 5,000/year) # Kalshi market anchor **KXAVGMEASLESDJT-29-5000: YES = 36.00%** (as of latest data). 30-day change: +5.00%; 7-day change: 0.00%. Price range over 44 observed days: 28%–70% (high volatility for a thin market). Average daily volume: only 292 contracts — low liquidity, so the 36% may reflect a handful of large trades rather than deep consensus. No adjacent-threshold markets (≥1,000/2,000/3,000) were returned by related-market search, so cross-threshold comparison is unavailable. # Sub-question answers 1. **2025 final CDC-confirmed count:** 2,289 confirmed cases for full-year 2025 (CDC, revised from initial 2,144 reported in Jan 2026) — the worst year since 1991/1992. [CDC.gov, AAP News] 2. **2026 YTD pace vs 2025:** As of mid-Aug 2026, CDC reports 2,566 cases YTD (94% outbreak-associated), already exceeding all of 2025's 2,289 total by July, with ~4+ months of the year remaining. Pace is running slightly ahead of 2025 but not dramatically so. [CDC.gov, NBC News, ABC News] 3. **Required rate for 2026–2028 to hit 5,000 avg:** With 2025 fixed at 2,289, 2026–2028 combined must total ~17,700 cases (avg ~5,900/yr) — roughly 2.3–2.6x the current annual pace, sustained for three consecutive years. [code_execution deterministic calc] 4. **Vaccination/exemption trends:** Kindergarten MMR coverage fell from 95.2% (2019–20) to 92.5% (2024–25), leaving ~286,000 kindergartners unprotected each cohort year; 93% of 2026 cases are unvaccinated/unknown status. Trend is gradual erosion, not a sudden collapse. [CDC.gov] 5. **Elimination status:** US elimination status is at risk; CDC/authorities to formally review status in November 2026. Canada already lost elimination status in Nov 2025. No confirmation yet the US has lost it. Epidemiologists call 2025–26 a "35-year high" but no official multi-year projection of case counts was found reaching 5,000+/yr. [US News, CIDRAP] 6. **Kalshi pricing:** Only the ≥5,000 threshold ticker was retrievable; adjacent buckets (≥1,000/2,000/3,000) returned no market data, so relative bucket calibration is unavailable from this pull. # Key facts (high-confidence, factual) 1. [CDC.gov] 2025 final case count: 2,289 confirmed cases, 48 outbreaks, 90% outbreak-associated, 3 deaths. 2. [CDC.gov/NBC/ABC] 2026 YTD (mid-Aug): 2,566 cases, already surpassing 2025's full-year total; 94% outbreak-associated. 3. [Wikipedia] 2025 Southwest US outbreak (Texas/NM Mennonite communities) was largest single driver of 2025 cases; declared over Aug 2025. 4. [CDC.gov] Kindergarten MMR coverage down to 92.5% (2024–25) from 95.2% (2019–20). 5. [code_execution] Deterministic math: hitting the 5,000 4-yr average requires 2026–2028 combined ~17,700 cases (~5,900/yr avg), a ~2.5x+ jump sustained three years running. 6. [code_execution Monte Carlo] Central probability estimate for 4-yr average ≥5,000 ≈ 5% (range ~2%–10% across sensitivity scenarios); crossing 5,000 sits near the 95th percentile of simulated outcomes. # Cross-market signals - Kalshi related: Only this single ticker found in series/keyword search; no adjacent-threshold markets returned for comparison/arbitrage. - Polymarket: No matching measles/CDC outbreak markets found (0/100 scanned). - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - Public health commentary (AAP, CIDRAP, WaPo investigation) frames 2025–26 as a genuine structural resurgence driven by declining vaccination coverage and "harder to stop" outbreaks than a decade ago, but none of the retrieved sources project multi-year average case counts anywhere near 5,000/yr. - CDC leadership vacancies (director, surgeon general) cited as a wildcard that could weaken outbreak response, a mild upside risk to case growth. [Medical Daily] - RFK Jr. (HHS) publicly urged vaccination despite the record case counts, suggesting no policy shift toward de-prioritizing MMR at the federal messaging level, a mild downside risk to further acceleration. [Yahoo/AP] # Directional lean per outcome - **Yes (≥5,000 avg):** Supported by accelerating 2026 pace (already past 2025's full-year total by July), declining vaccination coverage, elimination-status risk, and elevated Kalshi price (36%) suggesting market participants see meaningful tail risk. Opposed by: current 2-year average (~2,400/yr) sitting far below threshold; achieving 5,000 requires an unprecedented ~2.5–3x sustained multi-year jump, which Monte Carlo modeling puts at only ~5% central probability; no historical precedent for such levels in the post-2000 elimination era. - **No (<5,000 avg):** Supported by base-rate modeling (median simulated 4-yr average ~1,540; 95th percentile ~5,100), by 2025's confirmed 2,289 figure, and by the fact that even 2026's accelerated pace (~2,566 YTD through mid-Aug, likely ending near 4,000) still falls well short of the ~5,900/yr rate needed for the remaining years. Opposed by: possibility of federal response failures, further vaccination decline, and a genuinely large new interstate outbreak (echoing or exceeding 2025's Texas outbreak) recurring annually. # Gaps / unknowns - No 2026 full-year projection or final count yet (only through mid-August). - No confirmation of formal elimination-status loss (review pending November 2026). - Adjacent Kalshi threshold prices (≥1,000/2,000/3,000) unavailable, limiting bucket-relative calibration. - No epidemiological model explicitly targeting a 4-year 5,000+ average was found in raw research beyond the internally generated Monte Carlo estimate. # Calibration anchors - Kalshi current YES price: **36%** (anchor), up 5pts over 30 days, but thin volume (292/day avg) and wide historical range (28–70%) suggest low confidence/liquidity. - Precedent: worst pre-2025 year since elimination (2000) was ~1,274 cases (2019); 2025's 2,289 already doubled that. Reaching a 5,000/yr sustained average would be roughly 4x the previous record year, repeated for three straight years — a historically unprecedented scenario per Monte Carlo modeling (~5% central probability), creating tension with the market's 36% price that the forecaster should weigh carefully.

1. Both forecasts land well above the brief's own Monte Carlo central estimate (~5%, range 2-10%) without fully justifying why they diverge so far upward (24% and 16% vs ~5%); Forecast 1 explicitly argues the Monte Carlo "under-weights compounding exponential growth" but doesn't quantify what growth trajectory would be needed or why 2x-3x compounding is plausible for three consecutive years rather than a one-time outbreak spike (as 2025's Texas/Mennonite cluster was). 2. Neither forecaster addresses the strong possibility that 2026's YTD pace is inflated by a single large outbreak analogous to 2025's Southwest cluster (already "declared over Aug 2025"), meaning the 2,566 mid-year figure may not represent a new sustained baseline rate—this is a key sub-question ("2026 YTD pace vs 2025") that deserved more scrutiny about outbreak concentration/duration rather than treating it as steady-state growth. 3. Both forecasters discount the Kalshi 36% price as noise from thin liquidity, but neither considers the alternative explanation that informed traders may have information advantage (e.g., anticipating the November 2026 elimination-status review outcome) that the Monte Carlo model, built only on historical case-count extrapolation, cannot capture—this is a potential reference-class error in over-trusting the internally generated model over market pricing. 4. Neither forecast explicitly separates the scenario where the U.S. formally loses elimination status (pending Nov 2026 review) as a potential structural regime-change trigger that could shift the case-count distribution rather than a linear extrapolation—Canada's precedent is mentioned but its case-count implications (magnitude of Canada's post-loss trajectory) are not quantified or used to calibrate the "unprecedented" scenario. 5. Both forecasts settle in a narrow 16-24% band, showing convergence but potentially shared anchoring bias toward "splitting the difference" between the 36% market price and 5% model estimate rather than independently interrogating why the two diverge so much (7x)—this convergence could reflect anchoring on each other's plausible-sounding compromise rather than genuine independent evidence weighing. 6. The brief notes "no epidemiological model explicitly targeting a 4-year 5,000+ average was found" outside the internal Monte Carlo, yet both forecasters treat that Monte Carlo's ~5% as a quasi-authoritative baseline to adjust from, without flagging that it's a single, unvalidated internal simulation with unknown assumptions (e.g., growth-rate distributions, outbreak-recurrence modeling) that could itself be miscalibrated in either direction.

18% (56% confidence)

Yes: 18% No: 82%

With 2025 locked at 2,289 confirmed cases and 2026 tracking toward roughly 3,500–4,500, the market requires 2027–2028 to average ~6,500–7,000 cases each — about 3x the 2025 level and 5x the pre-2025 record (1,274 in 2019). That is a demanding structural break, and much of the 2025–26 signal is outbreak-cluster driven (Texas/Mennonite in 2025, ~94% outbreak-associated in 2026) rather than a proven new steady-state baseline, which argues against naive exponential extrapolation. However, the brief's ~5% Monte Carlo is a single unvalidated internal simulation that likely under-models fat-tailed outbreak recurrence: Canada's jump to ~5,000 cases post-elimination-loss, scaled per capita, shows US counts of that magnitude are epidemiologically feasible given a susceptible pool of ~286k unvaccinated kindergartners per cohort and a weakened federal response apparatus. I therefore sit meaningfully above the model but well below the thin, volatile 36% Kalshi anchor (292 contracts/day, 28–70% range), which I treat as noisy and upward-biased in a long-dated, low-liquidity tail market. Final: ~18% Yes.

Total pipeline time: 264.5s